| Literature DB >> 31693667 |
Jesper Kjærgaard1, Marilena Anastasaki2, Marianne Stubbe Østergaard3, Elvira Isaeva4, Azamat Akylbekov5, Nhat Quynh Nguyen6, Susanne Reventlow3, Christos Lionis2, Talant Sooronbaev7, Le An Pham8, Rebecca Nantanda9, James W Stout10, Anja Poulsen1.
Abstract
BACKGROUND: Respiratory disease and, specifically, pneumonia, is the major cause of mortality and morbidity in young children. Diagnosis of both pneumonia and asthma in primary care rests principally on clinical signs, history taking, and bronchodilator responsiveness. This study aimed to describe clinical practices in diverse global primary care settings concerning differential diagnosis of respiratory disease in young children, especially between pneumonia and asthma.Entities:
Mesh:
Year: 2019 PMID: 31693667 PMCID: PMC6834279 DOI: 10.1371/journal.pone.0221389
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Map of countries participating in the study and key health system indicators.
Characteristics of health professionals observed during consultations with children aged 2–59 months with respiratory symptoms in low-, middle-, and high-income, primary care settings.
| Greece | Kyrgyzstan | Vietnam | Uganda | Total | |
|---|---|---|---|---|---|
| Number of individual health professionals observed | 7 | 62 | 9 | 49 | 127 |
| Number of observations per health professional, median (IQR) | 6 (3–19) | 3 (2–5) | 12 (10–28) | 3 (1–8) | 4 (1–7) |
| Pediatrician | 72 (100) | 8 (3.4) | 208 (87.0) | 0 | 288 (37.3) |
| Internal Medicine Doctor | 0 | 0 | 10 (4.2) | 0 | 10 (1.3) |
| General Doctor | 0 | 36 (15.1) | 21 (8.8) | 20 (9.1) | 77 (10.0) |
| Anaesthesiologist | 0 | 0 | 0 | 16 (7.2) | 16 (2.1) |
| Clinical Officer | 0 | 104 (43.5) | 0 | 145 (65.6) | 249 (32.3) |
| Nurse | 0 | 90 (37.7) | 0 | 30 (13.6) | 120 (15.6) |
Information on class of health professional missing for
a: 1 observation
b: 1 observation
c: 0 observations
d:10 observations
Fig 2Number of consultations by class of health professional.
Characteristics of children aged 2–59 months observed during consultations for respiratory symptoms in low-, middle-, and high-income, primary care settings.
| Greece | Kyrgyzstan | Vietnam | Uganda | Total | |
|---|---|---|---|---|---|
| Number screened for cough and/or difficult breathing, n | 166 | 494 | 480 | 486 | 1626 |
| Number included in study and observed, n (% of screened) | 72 (43.4) | 239 (48.4) | 239 (49.8) | 221 (45.5) | 771 (47.4) |
| Maternal age in years, mean (SD) | 32·5 (5.8) [1] | 29·1 (6.0) [4] | 32·3 (6.7) [6] | 26·4 (5.1) [9] | 29·6 (6.4) [20] |
| Child age in months, median (IQR) | 42 (23.·5–54) [0] | 26 (14–38) [0] | 31 (19–46) [0] | 18 (7–30) [8] | 26 (13–42) [8] |
| Child sex, n female (%) | 31 (43.1) [0] | 114 (47.7) [0] | 106 (44.4) [0] | 104 (47.1) [20] | 355 (46·0) [20] |
| Duration of symptoms prior to consultation in days, median (IQR) | 3 (2–5) [2] | 4 (2–5) [6] | 3 (2–5) [95] | 3 (2–7) [73] | 3 (2–5) [176] |
| Previous attendance for cough/difficult breathing, n (%) | 43 (59.7) [1] | 156 (65.3) [4] | 186 (77.8) [2] | 184 (83.3) [4] | 596 (73.8) [11] |
| Number of previous attendances, n (%): | |||||
| 1 or 2 | 28 (38.9) | 105 (43.9) | 38 (15.9) | 53 (24.0) | 224 (29.1) |
| 3 or 4 | 7 (9.7) | 29 (12.1) | 48 (20.1) | 59 (26.7) | 143 (18.6) |
| 5 to 9 | 6 (8.3) | 21 (8.8) | 34 (14.2) | 31 (14.0) | 92 (11.9) |
| 10 or more | 1 (1.4) | 2 (0.8) | 57 (23.9) | 4 (1.8) | 64 (8.3) |
| No data on previous attendances | 30 (41.7) | 82 (34.3) | 62 (25.9) | 74 (33.5) | 248 (32.2) |
| Breathing difficulty at follow-up, n (%) | 12 (16.7) [5] | 2 (0.8) [8] | 12 (5.0) [31] | 23 (10.4) [90] | 49 (6.7) [134] |
| Follow-up time in days, median (IQR) | 5 (5–5) | 5 (5–5) | 5 (5–5) | 5 (5–5) | 5 (4–8) |
Numbers in [] represent data that is either missing or question not asked by healthcare professional.
History taking and clinical examination of children aged 2–59 months with respiratory symptoms during consultations in low-, middle-, and high-income, primary care settings.
| Greece | Kyrgyzstan | Vietnam | Uganda | Total | |
|---|---|---|---|---|---|
| Duration of consultation in minutes, median (IQR) | 15 (10–30) [14] | 20 (20–25) [0] | 3 (2–3) [0] | 4 (3–4) [4] | 5 (3–20) [18] |
| | |||||
| Fever | 63 (87.5) [1] | 118 (49.4) [4] | 131 (54.8) [0] | 75 (34.9) [6] | 387 (50.2) [11] |
| Difficult breathing during this illness | 38 (52.8) [1] | 36 (15.1) [4] | 6 (2.5) [0] | 16 (7.2) [7] | 96 (12.5) [12] |
| Wheezing during this illness | 6 (8.3) [0] | 0 (0) [0] | 26 (10.9) [1] | 5 (2.3) [7] | 37 (4.8) [8] |
| Noisy breathing | 7 (9.7) [1] | 10 (4.2) [5] | 0 (0) [0] | 8 (3.6) [6] | 25 (3.2) [12] |
| Night or early morning cough | 25 (34.7) [1] | 34 (14.2) [4] | 15 (6.3) [0] | 15 (6.8) [7] | 89 (11.5) [12] |
| | |||||
| Recurrent difficult breathing | 12 (16.7) [1] | 0 (0) [5] | 0 (0) [0] | 5 (2.3) [7] | 17 (2.2) [13] |
| Recurrent cough | 33 (45.8) [0] | 0 (0) [4] | 10 (4.2) [0] | 13 (5.9) [9] | 56 (7.3) [13] |
| At least one core respiratory symptom, except fever | 53 (73.6) [0] | 50 (20.9) [4] | 48 (20.1) [0] | 34 (15.4) [6] | 185 (24.0) [11] |
| History of triggers | 5 (6.9) [1] | 0 (0) [0] | 0 (0) [12] | 7 (3.2) [5] | 12 (1.6) [18] |
| Child or family history of asthma and/or allergy | 33 (45.8) [1] | 106 (44.4) [4] | 4 (1.7) [0] | 17 (7.7) [3] | 160 (20.8) [8] |
| Previous medications | 48 (66.7) [0] | 0 (0) [0] | 67 (28.0) [0] | 44 (19.9) [4] | 159 (20.6) [4] |
| Chest exposed | 72 (100) [0] | 219 (91.6) [4] | 222 (92.9) [0] | 47 (21.3) [9] | 560 (72.6) [13] |
| Respiratory rate counted | 72 (100) [0] | 24 (10.0) [6] | 60 (25.1) [0] | 24 (10.8) [9] | 180 (23.3) [15] |
| Chest wall in-drawing checked for | 41 (56.4) [1] | 0 (0) [6] | 0 (0) [0] | 23 (10.4) [16] | 64 (8.3) [33] |
| Stethoscope used | 72 (100) [0] | 227 (95.0) [4] | 219 (91.6) [0] | 35 (15.8) [15] | 553 (71.7) [19] |
| Temperature felt or measured | 46 (63.9) [0] | 100 (41.8) [4] | 57 (23.9) [0] | 94 (42.5) [8] | 297 (38.5) [12] |
| Referrals to secondary care | 5 (6.9) [2] | 8 (3.4) [4] | 15 (6.3) [5] | 22 (10.0) [28] | 50 (6.5) [39] |
Numbers in [] represent data that is either missing or question not asked by healthcare professional.
Diagnoses and treatments assigned to children aged 2–59 months presenting with respiratory symptoms in low-, middle-, and high-income, primary care settings.
| n (column %) | VURTI | Pneumonia | Tonsillitis | Bronchitis | Bronchiolitis | Asthma | Malaria | Other diagnosis | No diagnosis | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibiotics | 10 (33.3) | 1 (100) | 1 (100) | 6 (46.2) | - | - | - | 2 (40.0) | 3 (23.1) | 23 (31.9) | |
| Antivirals and cough medicine | 4 (13.3) | - | - | - | - | - | - | - | 1 (7.7) | 5 (6.9) | |
| SABA | 5 (16.7) | - | - | 11 (84.6) | 5 (71.4) | 2 (100) | - | - | 4 (30.8) | 27 (37.5) | |
| Corticosteroids | 3 (10.0) | - | - | 5 (38.5) | 2 (28.6) | - | - | - | 3 (23.1) | 13 (18.1) | |
| Supportive treatment | 1 (3.3) | - | - | - | - | - | - | 1 (20.0) | 1 (7.7) | 3 (4.2) | |
| No treatment | 8 (26.7) | - | - | - | - | - | - | 1 (20.0) | 2 (15.4) | 11 (15.3) | |
| Antibiotics | 80 (52.6) | 1 (50.0) | 9 (100) | 28 (59.6) | - | - | - | 16 (69.6) | - | 134 (56.1) | |
| Antivirals and cough medicine | 71 (46.7) | - | 2 (22.2) | 21 (44.7) | - | - | - | 6 (26.1) | - | 100 (41.8) | |
| SABA | - | - | - | - | - | - | - | - | - | - | |
| Corticosteroids | - | - | - | - | - | - | - | - | - | - | |
| Supportive treatment | - | - | - | - | - | - | - | - | - | - | |
| No treatment | 2 (1.3) | 1 (50.0) | - | 1 (2.1) | - | - | - | 1 (4.4) | 1 (16.7) | 6 (2.5) | |
| Antibiotics | 102 (63.8) | 6 (100) | 3 (100) | 32 (88.9) | 12 (70.6) | 1 (50.0) | - | - | - | 160 (67.0) | |
| Antivirals and cough medicine | 135 (84.4) | 3 (50.0) | 2 (66.7) | 26 (72.2) | 11 (64.7) | 1 (50.0) | - | - | - | 181 (75.7) | |
| SABA | 5 (3.1) | 4 (66.7) | 1 (33.3) | 22 (61.1) | 12 (70.6) | 1 (50.0) | - | - | - | 47 (19.7) | |
| Corticosteroids | 4 (2.5) | 1 (16.7) | - | 5 (13.9) | 3 (17.7) | - | - | - | - | 13 (5.4) | |
| Supportive treatment | - | - | - | - | - | - | - | - | - | - | |
| No treatment | - | - | - | - | - | - | - | - | - | - | |
| Antibiotics | 22 (22.9) | 14 (38.9) | - | - | 4 (57.1) | - | 20 (55.6) | 5 (50.0) | 4 (16.0) | 73 (33.0) | |
| Antivirals and cough medicine | - | - | - | - | - | - | - | - | - | - | |
| SABA | - | - | - | - | - | - | - | - | - | - | |
| Corticosteroids | - | - | - | - | - | - | 1 (2.8) | - | - | 1 (0.5) | |
| Supportive treatment | 44 (45.8) | 8 (22.2) | - | - | 3 (42.9) | - | 9 (25.0) | 1 (5.6) | 1 (4.0) | 66 (29.9) | |
| No treatment | - | - | - | - | - | - | - | - | - | - | |
| Antibiotics | 214 (48.9) | 22 (48.9) | 13 (100) | 66 (67.4) | 16 (51.6) | 1 (20.0) | 20 (55.6) | 27 (58.7) | 7 (15.9) | 390 (50.6) | |
| Antivirals and cough medicine | 210 (48.0) | 3 (6.7) | 4 (30.8) | 47 (48.0) | 11 (35.5) | 1 (20.0) | - | 6 (13.0) | 1 (2.3) | 286 (37.1) | |
| SABA | 10 (2.3) | 4 (8.9) | 1 (7.7) | 33 (33.7) | 17 (54.8) | 3 (60.0) | - | - | 4 (9.1) | 74 (9.6) | |
| Corticosteroids | 7 (1.6) | 1 (2.2) | - | 10 (10.2) | 5 (16.1) | - | 1 (2.8) | - | 3 (6.8) | 27 (3.5) | |
| Supportive treatment | 45 (10.3) | 8 (17.8) | - | - | 3 (9.7) | - | 9 (25.0) | 2 (4.4) | 2 (4.6) | 69 (9.0) | |
| No treatment | 10 (2.3) | 1 (2.2) | - | 1 (1.0) | - | - | - | 2 (4.4) | 3 (6.8) | 17 (2.2) | |
SABA: Short acting β-agonist, VURTI: Viral upper respiratory tract infection. Numbers in [] represent data that is either missing or question not asked by healthcare professional.
aIncluding cough medicine.
b Inhaled or oral.
c Consisting of children with the following diagnoses according to health professional report: acute respiratory tract infection, cold, coryza, flu, nasopharyngitis, pharyngitis, respiratory tract infection, upper respiratory tract infection, viral infection.
d Other diagnoses: e.g. croup, otitis, scarlet fever, stomatitis aphtosa, tracheitis, diarrhea.
e Supportive treatment: e.g. paracetamol, ibuprofen, antihistamines, fluids, and in Uganda also artemether/lumefantrine, mebendazole, vitamin A.
f Including bronchitis diagnoses with a variety of prefixes, e.g. acute, obstructive, allergic.
Fig 3Diagnosis assigned to children aged 2–59 months presenting with respiratory symptoms in low-, middle-, and high-income, primary care settings.
Use and effect of short acting β-agonist trials in children aged 2–59 months presenting with respiratory symptoms in low-, middle-, and high-income, primary care settings.
| Greece, n = 72 | Kyrgyzstan, n = 239 | Vietnam, n = 239 | Uganda | Total, N = 771 | |
|---|---|---|---|---|---|
| 28 (38.9) | - | 30 (12.6) | 4 (1.8) | 62 (8.0) | |
| 18 (64.3) | - | 10 (33.3) | 1 (25.9) | 29 (46.8) |
SABA: Short acting β-agonist
a: In Uganda, the majority of clinics only had oral SABAs available.
Human resources, amenities, equipment and medications available at participating primary care facilities.
| At pediatric ward | At health facility | Availability of amenities and equipment | Availability of medication | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Country | Level | Beds | Cots | Pediatricians | MDs | COs | Nurses | Electricity | Oxygen | Nebulizers | Spacers | SABA for nebulizer | MDI SABA | Oral SABA | ICS | OCS |
| Greece | Rural | 0 | 0 | 1 | 19 | 0 | 0 | |||||||||
| Rural | 0 | 0 | 1 | 6 | 0 | 1 | ||||||||||
| Rural | 2 | 1 | 1 | 10 | 0 | 3 | ||||||||||
| Rural | 1 | 0 | 1 | 8 | 0 | 2 | ||||||||||
| Kyrgyzstan | Rural | 0 | 0 | 0 | 1 | 0 | 5 | |||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 0 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 0 | 1 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 0 | 3 | ||||||||||
| Rural | 0 | 0 | 0 | 1 | 0 | 3 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 0 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 1 | ||||||||||
| Rural | 0 | 0 | 0 | 1 | 0 | 5 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 0 | ||||||||||
| Rural | 0 | 0 | 1 | 3 | 0 | 5 | ||||||||||
| Rural | 0 | 0 | 0 | 5 | 0 | 10 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 1 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 1 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 0 | 1 | ||||||||||
| Rural | 0 | 0 | 0 | 2 | 0 | 3 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 0 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 1 | ||||||||||
| Rural | 0 | 0 | 0 | 2 | 0 | 4 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 1 | ||||||||||
| Referral | - | - | - | 87 | - | 270 | ||||||||||
| Referral | 15 | 0 | 2 | 0 | 0 | 6 | ||||||||||
| Uganda | Rural | 3 | 1 | 0 | 2 | 2 | 2 | |||||||||
| Rural | 2 | 2 | 0 | 2 | 2 | 2 | ||||||||||
| Rural | 2 | 0 | 0 | 2 | 2 | 2 | ||||||||||
| Rural | 6 | 0 | 0 | 1 | 2 | 2 | ||||||||||
| Rural | 0 | 0 | 0 | 0 | 1 | 2 | ||||||||||
| Rural | 4 | 2 | 0 | 2 | 3 | 3 | ||||||||||
| Referral | 50 | 10 | 2 | 1 | 2 | 4 | - | |||||||||
| Vietnam | Rural | 35 | 4 | 3 | 0 | 2 | 3 | |||||||||
| Referral | 105 | 10 | 10 | 11 | 0 | 33 | ||||||||||
Answers according to color: Always (dark green); Often (green); Sometimes (yellow); Never (dark red); Yes (light green); No (red) MDs: medical doctors, COs: Clinical Officers, SABA: Short acting β-agonist, MDI: Metered dose inhaler, ICS: Inhaled corticosteroids, OCS: Oral corticosteroids